

UNCLASSIFIED

AD NUMBER
ADB262475
NEW LIMITATION CHANGE
TO Approved for public release, distribution unlimited
FROM Distribution authorized to U.S. Gov't. agencies only; Proprietary Info.; Oct 99. Other requests shall be referred to U.S. Army Medical Research and Materiel Command, 504 Scott St., Fort Detrick, MD 21702-5012.
AUTHORITY
USAMRMC ltr, 23 Aug 2001

THIS PAGE IS UNCLASSIFIED

AD _____

Award Number: DAMD17-97-1-7198

TITLE: Breast Tumor Specific Peptides: Development of Breast
Carcinoma Diagnostic and Therapeutic Agents

PRINCIPAL INVESTIGATOR: Thomas P. Quinn, Ph.D.

CONTRACTING ORGANIZATION: University of Missouri
Columbia, Missouri 65211

REPORT DATE: November 1999 _____

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Distribution authorized to U.S.
Government agencies only (proprietary information, Oct 99).
Other requests for this document shall be referred to U.S.
Army Medical Research and Materiel Command, 504 Scott Street,
Fort Detrick, Maryland 21702-5012.

The views, opinions and/or findings contained in this report are
those of the author(s) and should not be construed as an official
Department of the Army position, policy or decision unless so
designated by other documentation.

NOTICE

USING GOVERNMENT DRAWINGS, SPECIFICATIONS, OR OTHER DATA INCLUDED IN THIS DOCUMENT FOR ANY PURPOSE OTHER THAN GOVERNMENT PROCUREMENT DOES NOT IN ANY WAY OBLIGATE THE U.S. GOVERNMENT. THE FACT THAT THE GOVERNMENT FORMULATED OR SUPPLIED THE DRAWINGS, SPECIFICATIONS, OR OTHER DATA DOES NOT LICENSE THE HOLDER OR ANY OTHER PERSON OR CORPORATION; OR CONVEY ANY RIGHTS OR PERMISSION TO MANUFACTURE, USE, OR SELL ANY PATENTED INVENTION THAT MAY RELATE TO THEM.

LIMITED RIGHTS LEGEND

Award Number: DAMD17-97-1-7198

Organization: University of Missouri

Location of Limited Rights Data (Pages):

Those portions of the technical data contained in this report marked as limited rights data shall not, without the written permission of the above contractor, be (a) released or disclosed outside the government, (b) used by the Government for manufacture or, in the case of computer software documentation, for preparing the same or similar computer software, or (c) used by a party other than the Government, except that the Government may release or disclose technical data to persons outside the Government, or permit the use of technical data by such persons, if (i) such release, disclosure, or use is necessary for emergency repair or overhaul or (ii) is a release or disclosure of technical data (other than detailed manufacturing or process data) to, or use of such data by, a foreign government that is in the interest of the Government and is required for evaluational or informational purposes, provided in either case that such release, disclosure or use is made subject to a prohibition that the person to whom the data is released or disclosed may not further use, release or disclose such data, and the contractor or subcontractor or subcontractor asserting the restriction is notified of such release, disclosure or use. This legend, together with the indications of the portions of this data which are subject to such limitations, shall be included on any reproduction hereof which includes any part of the portions subject to such limitations.

THIS TECHNICAL REPORT HAS BEEN REVIEWED AND IS APPROVED FOR PUBLICATION.

Patricia O'Modran

12/26/02

REPORT DOCUMENTATION PAGE			Form Approved OMB No. 074-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503				
1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE November 1999		3. REPORT TYPE AND DATES COVERED Annual (1 Oct 98 – 1 Oct 99)
4. TITLE AND SUBTITLE Breast Tumor Specific Peptides: Development of Breast Carcinoma Diagnostic and Therapeutic Agents			5. FUNDING NUMBERS DAMD17-97-1-7198	
6. AUTHOR(S) Thomas P. Quinn, Ph.D.				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) University of Missouri Columbia, Missouri 65211 E-MAIL: bctquinn@muccmail.missouri.edu quinnt@missouri.edu			8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			10. SPONSORING / MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES This report contains colored photos				
12a. DISTRIBUTION / AVAILABILITY STATEMENT Distribution authorized to U.S. Government agencies only (proprietary information, Oct 99). Other requests for this document shall be referred to U.S. Army Medical Research and Materiel Command, 504 Scott Street, Fort Detrick, Maryland 21702-5012.				12b. DISTRIBUTION CODE
13. ABSTRACT (Maximum 200 Words) This proposal describes a body of research focused on the identification and development of peptides as breast tumor imaging and therapeutic agents. Peptides that bound the breast carcinoma associated Thomsen-Friedenreich (T) antigen and erbB-2 receptor were isolated from random peptide bacteriophage display libraries. A 15 amino acid peptide (P30) and a 6 amino acid peptide (P6.1) were shown to specifically bind T antigen and the erbB-2 extracellular domain, respectively. Both peptides bound breast carcinoma cells, but not normal human endothelial cells <i>in vitro</i> . The P30 peptide was shown to inhibit breast carcinoma cell homotypic aggregation and breast carcinoma endothelial cell adhesion. Tumor cell aggregation and adhesion to endothelial cells are thought to be important processes in metastasis. Inhibitors of these processes may provide important leads in the development of anti-metastatic therapeutics. Peptide 6.1 exhibited high specificity and affinity for breast cancer cells expressing erbB-2 on their surfaces. Analogs of P6.1 will be radiolabeled and examined for their potentials as breast tumor imaging or therapeutic agents.				
14. SUBJECT TERMS Breast Cancer			15. NUMBER OF PAGES 16	
			16. PRICE CODE	
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Limited	

NSN 7540-01-280-5500

Standard Form 298 (Rev. 2-89)
Prescribed by ANSI Std. Z39-18
298-102

FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the U.S. Army.

☒ Where copyrighted material is quoted, permission has been obtained to use such material.

☒ Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

☐ Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.

☒ In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and use of Laboratory Animals of the Institute of Laboratory Resources, national Research Council (NIH Publication No. 86-23, Revised 1985).

☒ For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

☒ In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

☒ In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

☒ In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.



PI - Signature

10/28/97
Date

TABLE OF CONTENTS:

Standard Form	ii
Foreword	iii
Table of Contents	iv
Introduction	1
Body	1
Key Research Accomplishments	4
Reportable Outcome	4
Conclusion	5
References	5
Appendix I	6
Figures 1-5	

INTRODUCTION:

The focus of our DoD funded research program is to identify peptides that specifically bind two breast tumor antigens, the Thomsen-Friedenreich (T) antigen and the ErbB-2 receptor, radiolabel the peptides with ^{99m}Tc and ^{188}Re , and determine the abilities of the radiolabeled peptides to target breast tumors in a scid mouse model system. The goal of this work is to develop breast tumor-avid peptides as potential *in vivo* imaging or therapeutic agents.

Background of previous work: T antigen is a disaccharide ($\text{Gal}\beta 1 \rightarrow 3 \text{GalNAc}$) which is masked on the surface of healthy cells, but is exposed and immuno-reactive on the surfaces of most tumor cells (1), including breast carcinoma cells (2). Peptides that bound T antigen were identified from a random peptide phage display library, screened with two glycoproteins which display T antigen on their surfaces, asialofetuin and a BSA-T conjugate. The peptide sequence with the best T antigen binding specificity and affinity was P30, His-Gly-Arg-Phe-Ile-Leu-Pro-Trp-Trp-Tyr-Ala-Phe-Ser-Pro-Ser. We had previously reported that P30 exhibited a $0.1 \mu\text{M}$ K_d for T antigen-bearing glycoproteins and bound MDA-MB435 breast carcinoma cells *in vitro* (3). The ^{99m}Tc -radiolabeled P30 peptide also bound breast tumor cells *in vitro*, but exhibited poor pharmacokinetics *in vivo*. *In vivo* clearance was slow and proceeded via hepatobiliary and GI paths. These results indicated that the radiolabeled P30 was not suitable for development into a breast cancer diagnostic agent. However, recent results indicate that the peptide itself possess anti-metastatic properties which may lead toward the development of breast carcinoma therapeutics.

The second research aim focuses on the identification of novel peptides that bind the erbB-2 receptor (4). ErbB-2, also known as HER-2 *or* neu is probably one of the best-studied proto-oncogenes frequently altered in human cancers. The erbB-2/HER-2/neu gene encodes a 185 kDa protein denoted p185, which can also be referred to as erb-2/HER-2/neu. Over expression of erbB-2 is associated with increased rates of tumor growth, enhanced rates of metastases, shorter disease-free survival, and reduced overall survival rates (4). Although erbB-2 is expressed at low levels in several normal organs and tissues (4), the elevated levels of erbB-2 in many human malignancies including breast carcinomas, and its extracellular accessibility makes it a very attractive target for the development of specific tumor agents. We previously described the identification of two peptide sequences that bound the extracellular domain of the erbB-2 receptor using random peptide bacteriophage display technology (5). The peptide sequences were chemically synthesized and examined for erbB-2 binding affinities and specificities. Peptide 6.1 (P 6.1), Lys-Cys-Cys-Tyr-Ser-Leu, exhibited optimal binding properties for the extracellular domain of erbB-2. The most recent results obtained with this peptide are reported below.

BODY:

I. T Antigen Project:

We have demonstrated that the P30 peptide bound T antigen containing glycoproteins and T antigen expressing breast carcinoma cells *in vitro*(3). Unfortunately, ^{99m}Tc -radiolabeled P30 displayed poor *in vivo* pharmacokinetics which were not consistent with further development into a diagnostic or therapeutic radiopharmaceutical. Alternatively, we hypothesized that the peptide itself might possess potential therapeutic properties based on its ability to mask T

antigen, an important cell surface ligand involved in cell adhesion. Tumor cell adhesion is an important step in metastasis. Understanding the molecular underpinnings of cancer metastasis is an important goal of modern cancer research. Metastasis is a multi-step process involving many cell-cell and cell-extracellular matrix interactions. Several of these steps include interactions between cell surface molecules such as carbohydrates, lectins, and extracellular matrix proteins participating in cell-cell recognition and adhesion (6, 7). While the initial steps of metastasis include detachment of malignant cells from the primary tumor and migration into the circulatory system, subsequent steps involve malignant cells adhering to each other (homotypic aggregation) or to host cells (heterotypic adhesion) (8-11) to form multicellular aggregates. Eventually, the circulating tumor cells become either non-specifically lodged in small capillaries or specifically bind to capillary endothelial cells and exposed basement membrane proteins, resulting in the formation of secondary tumor sites. It has been suggested that cellular adhesion is in part mediated by specific interactions between cell surface lectins and carbohydrates present on glycoproteins, glycolipids, and glycosaminoglycans (7, 9, 12,).

Involvement of Thomsen-Friedenreich (T) antigen in homotypic aggregation of MDA-MB-435 human breast carcinoma cells. Multicellular aggregate formation is an important feature of metastatic cancer cells directly correlating with their increased survival potential *in vitro* (13) and metastatic propensity *in vivo* (14). The cancer associated T antigen has been implicated in tumor cell adhesion through carbohydrate-lectin interactions (1, 15). We previously reported the expression of large quantities of T antigen on the surface of MDA-MB-435 cells confirmed by binding of T antigen specific PNA lectin (3). In this study, we investigated the role of T antigen in homotypic aggregation of the MDA-MB-435 breast cancer cells. Tumor cells collected from subconfluent (70-80%) cultures were allowed to form multicellular aggregates. The direct binding of T antigen specific PNA lectin conjugated to horseradish peroxidase followed by color reaction with DAB was used to visualize T antigen. The cytochemical analysis of the samples containing multicellular aggregates revealed significant accumulation of T antigen at the sites of cell contacts (Fig. 1 A), suggesting participation of T antigen in homotypic aggregation of MDA-MB-435 breast carcinoma cells. Consistent with this is the fact that addition of different concentrations of synthetic T antigen specific peptide, P-30 (HGRFILPWWYAFSPS), inhibited homotypic aggregation of MDA-MB-435 cells in a dose dependent manner (Fig. 1 B). A maximum inhibitory effect (over 70%) was achieved at a peptide concentration of 0.1 mg/ml. The control peptide (RRLIFYKYVYKRYRAGKQRG) which does not interact with T antigen (3) failed to inhibit homotypic aggregation of MDA-MB-435 cells (Fig. 1 C, D, and E). These findings, as well as the previously reported ability of P-30 to inhibit asialofetuin mediated aggregation of mouse melanoma cells (3) suggest that the effect of P-30 on homotypic aggregation of MDA-MB-435 cells is T antigen specific.

Adhesion of MDA-MB-435 breast carcinoma cells to the endothelium. Since T antigen (Gal β 1 $\rightarrow$ 3GalNAc) has β -galactose as a terminal sugar, it is likely that T antigen mediated interactions may involve participation of β -galactoside specific lectins (galectins). Thus, it was of interest to analyze whether β -galactoside specific lectins participate in adhesion of the MDA-MB-435 cells to the endothelium. Confocal laser microscopy revealed clustering of both galectin-

1 and galectin-3 to the sites of contact between MDA-MB-435 cells and human umbilical endothelial cells (Fig. 2 A and B) indicative of their involvement in the interaction between cancer and endothelial cells. We could not observe, however, any signs of galectin-4 participation in this process consistent with the data on its low level of expression in MDA-MB-435 cells. Interestingly, galectin-1 and galectin-3 reacted differently on tumor and endothelial cells. A strong galectin-1 signal accumulated at the sites of tumor-endothelial cell contact predominantly on the cancer cells (Fig. 2 A) suggesting the involvement of one or more of its cognate ligands on the endothelium. Galectin-3 in contrast, while also being strongly expressed on the tumor cells, clearly demonstrated signal accumulation toward the sites of the cell contact on HUVEC (Fig. 2 B) possibly interacting with T antigen or the other putative ligands on cancer cells. We hypothesized that if galectin-3 on the endothelial cells interacts with T antigen on MDA-MB-435 cells then T antigen specific P-30 should inhibit this interaction as it did in the case of homotypic aggregation. Thus we performed experiments in which cancer cells were allowed to adhere to a monolayer of endothelial cells in the presence of P-30 (0.1 mg/ml final concentration) or a control peptide of identical concentration. The results of these experiments (Fig. 2 C, D, and E) showed that the control peptide did not effect the adhesion of the MDA-MB-435 cells to the endothelial cells (Fig. 2 C and D) while T antigen specific P-30 significantly inhibited it (Fig. 2 E). When adhesion experiments were performed with different concentrations of P-30 we found the peptide's effect to be dose dependent with the maximal inhibition achieved up to 50% (Fig. 3). These data demonstrated that adhesion of the MDA-MB-435 human breast carcinoma cells to the endothelial cells was at least in part mediated by T antigen.

II. ErbB-2 Receptor-Avid Peptide Characterization:

Peptide sequences, originally identified from random peptide bacteriophage libraries affinity selected with recombinant erbB-2 extracellular domain, were chemically synthesized using Fmoc solid phase peptide synthesis (Table 1). The peptides were cleaved from the support resin, deprotected, and purified by high performance liquid chromatography (HPLC). Mass spectrometry was used to confirm the expected molecular weights of the synthetic peptides. N-terminally biotinylated analogs of the peptide sequences were also synthesized as described above. Due to the limited solubility of P15 and biotinylated P15 in aqueous solutions, we have focus on the characterization of P6.1

Table 1. Peptide Sequences Identified from Bacteriophage Display Libraries.

<u>Peptide Name</u>	<u>Peptide Sequence</u>
P6.1	Lys-Cys-Cys-Tyr-Ser-Leu
P15	Trp-Arg-Arg-Trp-Phe-Tyr-Gln-Phe-Pro-Thr-Pro-Leu-Ala-Ala-Ala

In vitro P6.1 Breast Carcinoma Binding Assay. The ability of the P6.1 to recognize a native conformation of the erbB-2 expressed on a surface of human cancer cells was examined *in situ*. The expression of erbB-2 on MDA-MB-435 human breast carcinoma cells has been reported previously (4). In a double immunostaining experiments both Neu(9G6) anti-erbB-2 mouse monoclonal antibody and biotinylated P6.1 bound MDA-MB-435 human breast carcinoma cells (Figure 4 B and C). This is consistent with the data of ELISA experiments suggesting that antibody and peptide do not compete for the binding sites on the erbB-2 extracellular domain. The biotinylated control peptide did not bind MDA-MB-435 cells (data not shown). Neither Neu(9G6) anti-erbB-2 antibody nor biotinylated P6.1 bind T-24 human bladder carcinoma cells, which do not express T antigen on their surfaces (Figure 4 e and f).

P6.1 Binding Specificity and Affinity. The specificity of P6.1 peptide to the recombinant extracellular domain of erbB-2 was examined by slot-blotting and ELISA procedures. Affinity purified recombinant extracellular domain of erbB-2 and commercially available proteins: BSA, asialofetuin, and human IgG were immobilized on nitrocellulose paper in serial dilutions and visualized by the biotinylated peptide. At 15 – 7.5 ng immobilized protein, peptide P6.1 bound only erbB-2 and did not react with control proteins (Fig 5 A). The further analyses were performed to compare binding activity of P6.1 with the binding of control peptide. The binding affinity of the peptide to extracellular domain of erbB-2 was quantitatively evaluated using fluorescence titration experiments. Samples of protein were titrated with increasing concentration of peptide. The quenching of tryptophane fluorescence was measured and used to generate binding curves (Fig 5 B). The data were collected at 2 μ M, 4 μ M and 6 μ M concentrations of erbB-2. The equilibrium binding constant $K_d = 30.21 \pm 7.59 \mu$ M was determined using a single binding site curve-fitting procedure. The control peptide did not show any specific binding as assayed by fluorescence quench titration analysis (data not shown).

KEY RESEARCH ACCOMPLISHMENTS:

- The T antigen binding peptide P30 inhibits breast cancer tumor cell homotypic aggregation and heterotypic tumor cell endothelial cell adhesion *in vitro*.
- A six amino acid peptide, originally identified from a random peptide bacteriophage display library affinity selected with the extracellular domain of erbB-2, binds breast carcinoma cells that express the erbB-2 receptor on their surfaces.

REPORTABLE OUTCOMES:

- 2 manuscripts are in preparation.

-Funding for an additional postdoctoral fellow was obtained from the Cancer Research Center.

CONCLUSIONS:

Multicellular aggregate formation and adhesion of tumor cells to the endothelium are crucial events during early stages of cancer metastasis. Taken together our data indicated that β -galactoside and particularly T antigen mediated cell-cell interactions are important components of these events. To the best of our knowledge this is the first observation showing directly the accumulation of galectin-1 and galectin-3 at sites of contact between cancer and endothelial cells indicative of their active participation in adhesion of tumor cells to the endothelium. Strikingly different behavior of these two β -galactoside specific lectins reflects the complexity of the adhesion process. The accumulation of galectin-1 at the sites of cell-cell contacts predominantly on cancer cells and galectin-3 on endothelial cells suggests that several of their cognate ligands might be simultaneously involved here on both tumor and endothelial cells. Inhibition of tumor cell adhesion by the T antigen specific P-30 peptide, however, highlights an active role for this cell surface carbohydrate structure in cancer-endothelial cell interactions. The ability of a short synthetic peptide to effectively interfere with this line of intercellular communication may also be of functional significance for the development of new anti-adhesive therapies of cancer metastasis.

REFERENCES:

1. Springer, G. F. *Science* **224**, 1198-1206, 1985.
2. Springer, G. F. *Molecular Immunology* **26**, 1-5, 1989.
3. Peletskaya, E.N., Glinsky, V.V., Glinsky, G.V., Deutscher, S.L., and Quinn, T.P. *J. Mol. Biol.* **270**, 374-384, 1997.
4. Hynes, N.E. And Stern, D.F. *Biochemica et Biophysica Acta* **1198**, 165-184, 1994.
5. USAMRMC DAMD-17-97-1-7198, Progress Report 1998.
6. Hakomori, S-I. Aberrant glycosylation in tumors and tumor-associated carbohydrate antigens. *Advan. Cancer Res.*, **52**, 257-331, 1989.
7. Hakomori, S-I. *Current Opinion in Immunology*, **3**, 646-653, 1991.
8. Graves, D. *Br. J. Cancer*, **48**, 665-673, 1983.
9. Meromsky, L., Lotan, R., and Raz, A. *Cancer Research*, **46**, 5270-5275, 1986.
10. Springer, G. F. and Desai, P. R. *Biochem. Biophys. Res. Commun.*, **61**, 470-475, 1974.
11. Springer, G.F., Cheingsong-Popov, R., Schirmmacher, V., Desai, P.R., Tegtmeier, H. *J. Biol. Chem.*, **258**:9, 5702-5706, 1983.
12. Fukuda, M. (1994) *In, Frontiers in Molecular Glycobiology*, (Fukuda and Hindsgaul, eds.) vol. 1, Oxford University Press, Oxford.
13. Glinsky, G.V., and Glinsky, V.V. *Cancer Letters*, **101**, 43-51, 1996.
14. Fidler, I.J. *Eur. J. Cancer*, **9**, 223-227, 1975.
15. Kishikawa, T., Ghazizadeh, M., Sasaki, Y., and Springer, G.F. *Jpn. J. Cancer Res.*, **90**:3, 326-332, 1999.

APPENDIX I

FIGURES




Figure 1

A. Direct binding of T antigen specific peanut (PNA) lectin to the MDA-MB-435 human breast carcinoma cells. Note the accumulation of T antigen at the sites of the cell-cell contact indicated by arrows. B. Dose dependent inhibition of spontaneous homotypic aggregation of the MDA-MB-435 human breast carcinoma cells by T antigen specific peptide P-30. C, D, and E - inhibition of spontaneous homotypic aggregation of MDA-MB-435 human breast carcinoma cells by 0.1 mg/ml of synthetic P-30 (E), but not by the same concentration of the control peptide (D) compared to the control (C).




Figure 2

Involvement of the galectin-1 (A) and galectin-3 (B) in adhesion of the MDA-MB-435 human breast carcinoma cells to the monolayer of human umbilical endothelial cells as revealed by laser confocal microscopy. The X-Z sections shown were obtained as described in materials and methods using 60x lens. The images were thresholded and pseudocolored (galectin-1 – green, galectin-3 – red). Note the clusterization toward the cell contacts of galectin-1 on cancer cells (A) and galectin-3 on endothelial cells (B), indicated with arrows. The superimposed fluorescent photomicrographs of DiI labeled MDA-MB-435 breast cancer cells adhered to the monolayer of HUVEC cells (C, D, and E). Note inhibition of the adhesion by 0.1 mg/ml of the T antigen specific synthetic P-30 (E), but not by the same concentration of the control peptide (D) compared to the control (C).




Figure 3

Dose dependent inhibition of the adhesion of MDA-MB-435 human breast carcinoma cells to the endothelium by synthetic T antigen specific peptide P-30. The maximum inhibitory effect (about 50%) was achieved at 0.1 mg/ml concentration of the peptide.






Figure 4

The ability of the P6.1 to recognize a native conformation of the *erbB-2* expressed on a surface of human cancer cells was examined in situ. In a double immunostaining experiments both Neu(9G6) anti-*erbB-2* mouse monoclonal antibody and biotinylated P6.1 bound human breast carcinoma cells MDA-MB-435 (Fig. 4 B and C respectively). This is consistent with the data of ELISA experiments suggesting that antibody and peptide do not compete for the binding sites on the *erbB-2* extracellular domain. The biotinylated control peptide did not bind MDA-MB-435 cells (data not shown). Neither Neu(9G6) anti-*erbB-2* antibody no biotinylated P6.1 bind T-24 human bladder carcinoma cells, which do not express *erbB-2* (Fig. 4 E and F).



A



B

Fig5. A – Slot-blot binding assay. BSA (A), recombinant extracellular domain of erbB-2 (B), bovine asialofetuin (C) and human IgG (D) immobilized on nitrocellulose paper in different amounts were incubated with the biotinylated peptide and visualized by streptavidin-alkaline phosphatase. B – Determination of affinity constant by fluorescence titration. Data used for generation of binding isotherms were obtained at three different concentration of erbB-2: 0.6 μM , 0.4 μM , 0.2 μM .



DEPARTMENT OF THE ARMY
US ARMY MEDICAL RESEARCH AND MATERIEL COMMAND
504 SCOTT STREET
FORT DETRICK, MARYLAND 21702-5012

REPLY TO
ATTENTION OF:

MCMR-RMI-S (70-1y)

23 Aug 01

MEMORANDUM FOR Administrator, Defense Technical Information
Center (DTIC-OCA), 8725 John J. Kingman Road, Fort Belvoir,
VA 22060-6218

SUBJECT: Request Change in Distribution Statement

1. The U.S. Army Medical Research and Materiel Command has reexamined the need for the limitation assigned to the technical reports listed at enclosure. Request the limited distribution statement for these reports be changed to "Approved for public release; distribution unlimited." These reports should be released to the National Technical Information Service.

2. Point of contact for this request is Ms. Judy Pawlus at DSN 343-7322 or by e-mail at judy.pawlus@det.amedd.army.mil.

FOR THE COMMANDER:

Encl


PHYLIS M. RINEHART
Deputy Chief of Staff for
Information Management

Reports to be Downgraded to Unlimited Distribution

ADB241550	ADB253628	ADB249654	ADB263448
ADB251657	ADB257757	ADB264967	ADB245021
ADB263525	ADB264736	ADB247697	ADB264544
ADB222448	ADB255427	ADB263453	ADB254454
ADB234468	ADB264757	ADB243646	
ADB249596	ADB232924	ADB263428	
ADB263270	ADB232927	ADB240500	
ADB231841	ADB245382	ADB253090	
ADB239007	ADB258158	ADB265236	
ADB263737	ADB264506	ADB264610	
ADB239263	ADB243027	ADB251613	
ADB251995	ADB233334	ADB237451	
ADB233106	ADB242926	ADB249671	
ADB262619	ADB262637	ADB262475	
ADB233111	ADB251649	ADB264579	
ADB240497	ADB264549	ADB244768	
ADB257618	ADB248354	ADB258553	
ADB240496	ADB258768	ADB244278	
ADB233747	ADB247842	ADB257305	
ADB240160	ADB264611	ADB245442	
ADB258646	ADB244931	ADB256780	
ADB264626	ADB263444	ADB264797	